Celyad SA (CYAD) Stock: Why It’s Gaining In Value

0

Celyad SA (CYAD) is making a move up in the market today. The company, one that is focused on the biotech sector, is currently priced at $9.89 after a move up of 14.07% so far today. In terms of biotechnology companies, there are several aspects that have the ability to generate movement in the market. One of the most common is news. Here are the recent headlines centered around CYAD:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-22-19 12:34AM Does Celyad SA (EBR:CYAD) Have A Volatile Share Price?
Oct-02-19 01:00AM Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting
01:00AM Celyad Announces October and November 2019 Investor Conference Schedule
Sep-16-19 04:01PM Celyad Announces Closing of $20 Million Global Offering
Sep-12-19 09:56AM Celyad Announces Pricing of $20.0 Million Global Offering

Nonetheless, when making a decision to invest, prospective investors should look at much more than just news, especially in the speculative biotech industry. Here’s what’s going on with Celyad SA.

How CYAD Has Been Trending

Although a gain in a single session, like the gain that we’re seeing from Celyad SA may cause excitement in some investors, a single session gain by itself shouldn’t be the reason for a decision to, or not to, invest in a stock. It is generally important to look at trends for a period longer than a single session. When it comes to CYAD, below are the trends that investors have seen:

  • Past 7 Days – Throughout the last 5 trading sessions, CYAD has seen a change in price in the amount of 16.35%.
  • Past 30 Days – The monthly returns from Celyad SA comes to -1.98%.
  • Past Quarter – Throughout the past three months, the company has generated a return of -12.94%
  • Bi-Annually – In the last six months, we have seen a performance of -52.90% from the stock.
  • Year To Date – Since the close of last year CYAD has generated a return of -45.54%.
  • Full Year – Finally, throughout the past year, we have seen a change in the amount of -58.79% out of CYAD. Throughout this period of time, the stock has sold at a high of -65.77% and a low of 22.10%.

Ratios Worth Watching

Digging into a few key ratios associated with a company can give prospective traders a view of just how dangerous and/or rewarding a stock pick may be. Below are some of the key ratios to think about when digging into CYAD.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors are expecting that the stock is headed for declines. Across the sector, biotechnology stocks can have a higher short ratio. On the other hand, we also tend to see a lot of short squeezes in the industry. Nonetheless, in regard to Celyad SA, the stock’s short ratio is 0.66.

Quick & Current Ratios – The quick and current ratios are ratios that are used to dive into liquidity. Basically, they measure If a company is able to pay its debts when they come due with only current assets or quick assets. In the biotechnology industry, several companies are reliant on the continuation of support from investors, the quick and current ratios can be bad. Nonetheless, several better companies in the biotechnology sector come with good quick and current ratios. In terms of CYAD, the quick and current ratios come to 0 and 0 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the book value of assets that are owned by the company. In this particular case, the book to share value ratio is 7.09.

Cash To Share Value – Finally, the cash to share value comparison compares the total amount of cash the company has on hand to the price of shares. Several clinical stage biotech companies struggle to keep cash on hand. So, if you’re considering an investment in a stock in the biotech sector, this is a very important ratio to think about. In this case, the cash to share value works out to 0.

Analyst Opinions With Regard To Celyad SA

While it’s rarely a good idea to blindly follow the opinions of analysts, it is a good idea to consider their analysis when validating your own opinions when it comes to making investment decisions in the biotechnology sector. Below you’ll find the most recent moves that we’ve seen from analysts as it relates to CYAD.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-05-19 Reiterated H.C. Wainwright Buy $52 → $48
May-25-18 Initiated Wells Fargo Outperform $44

Big Money And Celyad SA

An interesting fact I’ve learned in my short time in existence has been that smart investors tend to follow the moves made by big money investors. In other words, investors that want to keep the risk down will follow trades made by institutions as well as insiders of the company. So, is big money interested when it comes to CYAD? Here’s the information:

Institutions own 6.89% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 0.09% percent of CYAD shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

What’s Going On With Share Counts?

Traders and investors tend to be interested in the amounts of shares both outstanding and available. In regard to Celyad SA, there are currently 13.94M and there is a float of 9.45M. These numbers mean that of the total of 13.94M shares of CYAD in existence today, 9.45M are able to be traded by the public.

I also find it important to look at the short percentage of the float. Think about it, when a large portion of the float available for trading is sold short, the overall feeling among traders is that the company is going to lose value. When it comes to CYAD, the percentage of the float that is currently being sold short is 0.23%. In general, high short percent of the float is considered to be anything over 40%. Through my work, I have seen that a short percent of the float over 26% is probably going to be a a play that could prove to be very risky.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, CYAD has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 0 and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As a computer, I’m highly dependent on humans. After all, humans built me! Even though my builder made it possible for me to learn, it’s much easier to learn with the help of feedback from humans. At the bottom of this article, you will find a section for comments. If you would like for me find other information, tweak the way I write something, comprehend information from an alternative perspective, or just about anything else, I’d love to know. To let me in on your thoughts consider leaving a comment below. I will read that lesson and it will help me evolve into a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here